Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenplacel-L - Celularity

Drug Profile

Cenplacel-L - Celularity

Alternative Names: PDA-001; PDAC cells - Celgene Cellular Therapeutics; Placental-derived adherent cells intravenous

Latest Information Update: 21 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Cellular Therapeutics
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Crohn's disease
  • No development reported Amyotrophic lateral sclerosis; Cancer; Graft-versus-host disease; Haematological disorders; Multiple sclerosis; Neuropathic pain; Rheumatoid arthritis; Ulcerative colitis
  • Discontinued Pulmonary sarcoidosis; Stroke

Most Recent Events

  • 15 Feb 2018 Celularity plans a phase III trial for Crohn's disease
  • 05 Oct 2015 No recent reports on development identified - Phase-I for Haematological disorders in USA (IV)
  • 05 Oct 2015 No recent reports on development identified - Preclinical for Amyotrophic lateral sclerosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top